Lipocine(NASDAQ) LPCN

Market Cap$17.64M

Since IPO (2013)-99%

5 Year-91%

1 Year-38%

1 Month-13%

$2.16

+3.85%

+0.08Today

Lipocine last closing stock price
Metric	Price	Date
Last close	USD 2.14	2026-07-27

Lipocine stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.47%	USD 2.15	2026-07-20
1 month	-13.01%	USD 2.46	2026-06-26
3 month	-7.36%	USD 2.31	2026-04-28
Year to date	-73.35%	USD 8.03	2025-12-31
1 year	-37.79%	USD 3.44	2025-07-25
3 year	-56.42%	USD 4.91	2023-07-28
5 year	-90.61%	USD 22.78	2021-07-28
Since inception	-99.37%	USD 340.00	2013-08-28

Lipocine Financials at a Glance

Market Cap

$17.64M

Revenue (TTM)

$2.00M

Net Income (TTM)

-$11.43M

EPS (TTM)

-$1.96

P/E Ratio

-1.09

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Price

$2.16

Volume

144

Open

$2.15

Price

$2.16

Volume

144

Open

$2.15

Previous Close

$2.16

Daily Range

$2.15 - $2.16

52-Week Range

$1.81 - $12.37

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Price

$2.16

Volume

144

Open

$2.15

Previous Close

$2.16

Daily Range

$2.15 - $2.16

52-Week Range

$1.81 - $12.37

Estimated Earnings Date

Aug 4, 2026

LPCN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lipocine

Lipocine Inc. is a pharmaceutical company specializing in the development of oral therapies for endocrine and metabolic disorders. The company leverages proprietary drug delivery technology to enhance absorption and bioavailability of medications traditionally administered via injection. This innovative approach aims to improve patient compliance and quality of life.

Products and Services

Lead product candidate for testosterone deficiency utilizing novel oral delivery method

Pipeline of therapies targeting neuroendocrine tumors

Partnerships and clinical trials to expand product portfolio

What Makes Lipocine Inc. Special

Lipocine's technology enables oral delivery of drugs that are usually injected, offering a convenient and effective alternative. This positions the company to address unmet medical needs and provides a competitive advantage in the pharmaceutical sector.

Five Things You Need to Know

Lipocine Inc. focuses on endocrine and metabolic disorders.

Its proprietary technology enhances drug absorption and bioavailability.

The lead candidate aims to improve testosterone deficiency treatments.

An experienced management team drives drug development and commercialization.

The company seeks growth through clinical trials and strategic partnerships.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Mahesh V. Patel, PhD

Website

www.lipocine.com

Headquarters

Salt Lake City, UT 84108, US

LPCN Financials

Key Financial Metrics (TTM)

Gross Margin

-8.21%

Operating Margin

-605.86%

Net Income Margin

-571.10%

Return on Equity

-66.69%

Return on Capital

-69.48%

Return on Assets

-45.09%

Earnings Yield

-91.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.64M

Shares Outstanding

8.24M

Volume

144

Avg. Volume

85.64K

Financials (TTM)

Gross Profit

-$164.35K

Operating Income

-$12.13M

EBITDA

-$11.37M

Operating Cash Flow

-$10.05M

Capital Expenditure

$1.00

Free Cash Flow

-$10.05M

Cash & ST Invst.

$24.73M

Total Debt

$0.00

Lipocine Performance Analysis

Lipocine annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 500,000	-96.9%
2023	2023-12-31	USD 109,987	-78.0%
2024	2024-12-31	USD 11,198,144	10081.3%
2025	2025-12-31	USD 1,976,677	-82.3%

Lipocine sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	563.6%
Q3	2025-09-30	-81.6%
Q4	2025-12-31	899.7%
Q1	2026-03-31	-89.6%

Lipocine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.07	1566.2%
2023	2023-12-31	USD -3.14	52.0%
2024	2024-12-31	USD -0.00	-99.9%
2025	2025-12-31	USD -1.77	110331.3%

Lipocine sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-17.1%
Q3	2025-09-30	-43.9%
Q4	2025-12-31	28.8%
Q1	2026-03-31	-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$119.40K

+27.2%

Gross Profit

$104.58K

+11.4%

Gross Margin

87.59%

N/A

Market Cap

$17.64M

N/A

Market Cap/Employee

$1.26M

N/A

Employees

N/A

Net Income

-$3.67M

-96.9%

EBITDA

-$3.66M

-97.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$24.73M

+25.4%

Total Debt

$0.00

N/A

Accounts Receivable

$111.41K

-37.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-45.09%

N/A

Return on Invested Capital

-53.13%

N/A

Free Cash Flow

-$2.26M

-14.6%

Operating Cash Flow

-$2.26M

-14.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PMNProMIS Neurosciences, Inc.

PMNProMIS Neurosciences, Inc.$11.72-3.93%

BLRXBioLineRx Ltd.

BLRXBioLineRx Ltd.$2.82-0.11%

MBRXMoleculin Biotech, Inc.

MBRXMoleculin Biotech, Inc.$2.19+3.30%

OSRHOSR Holdings, Inc.

OSRHOSR Holdings, Inc.$0.43+2.44%

LNAILunai Bioworks Inc.

LNAILunai Bioworks Inc.$2.23-4.29%

ERNAErnexa Therapeutics Inc.

ERNAErnexa Therapeutics Inc.$3.92-0.25%

GOVXGeoVax Labs, Inc.

GOVXGeoVax Labs, Inc.$0.76+3.93%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.23+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.88+0.03%

Questions About LPCN

What is the current price of Lipocine?

Lipocine is trading at $2.16 per share.

What is the 52-week range for Lipocine?

Over the past 52 weeks, Lipocine has traded between $1.81 and $12.37.

How much debt does Lipocine have?

As of the most recent reporting period, Lipocine reported total debt of $0.00.

How much cash does Lipocine have on hand?

Lipocine reported $5.02M in cash and cash equivalents in its most recent financial results.

What is Lipocine’s dividend yield?

Lipocine does not currently have a dividend yield.

Lipocine(NASDAQ) LPCN

Lipocine Financials at a Glance

LPCN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Lipocine

Products and Services

What Makes Lipocine Inc. Special

Five Things You Need to Know

LPCN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Lipocine Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LPCN

What is the current price of Lipocine?

What is the 52-week range for Lipocine?

How much debt does Lipocine have?

How much cash does Lipocine have on hand?

What is Lipocine’s dividend yield?

Premium Investing Services